XTL Biopharmaceuticals Ltd.
Clinical-stage biopharmaceutical company developing drugs for autoimmune diseases.
XTLB | TA
Overview
Corporate Details
- ISIN(s):
- IL0010854979
- LEI:
- 529900NDDXEAPTUTXP41
- Country:
- Israel
- Address:
- 5 HaCharoshet St., 4365603 Raanana
- Website:
- https://www.xtlbio.com
- Sector:
- Manufacturing
Description
XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-19 14:04 |
Immediate Report of Meeting to be held on December 19,2022-Scribal error
|
English | 1.8 MB | ||
| 2021-12-19 14:04 |
Immediate Report of Meeting to be held on December 19,2022-Scribal error
|
English | 118.8 KB | ||
| 2021-12-17 01:35 |
Immediate Report of Meeting to be held on January 19,2022
|
English | 1.8 MB | ||
| 2021-12-17 01:35 |
Immediate Report of Meeting to be held on January 19,2022
|
English | 115.6 KB | ||
| 2021-11-24 19:00 |
financial results for the nine months ended September 30, 2021
|
English | 146.2 KB | ||
| 2021-11-24 19:00 |
financial results for the nine months ended September 30, 2021
|
English | 36.0 KB | ||
| 2021-08-24 23:05 |
Financial Results for a Period of Six Months Ending June 30, 2021
|
English | 211.4 KB | ||
| 2021-08-24 23:05 |
Financial Results for a Period of Six Months Ending June 30, 2021
|
English | 36.0 KB | ||
| 2021-06-09 17:32 |
Final Prospectus-June 7, 2021
|
English | 298.7 KB | ||
| 2021-06-09 17:32 |
Final Prospectus-June 7, 2021
|
English | 36.0 KB | ||
| 2021-06-02 23:17 |
Post Effective Amendment No.1 to Form F-1 on Form F-3
|
English | 411.0 KB | ||
| 2021-06-02 23:17 |
Post Effective Amendment No.1 to Form F-1 on Form F-3
|
English | 36.0 KB | ||
| 2021-05-19 21:18 |
Financial Results for the Three Months Ended March 31, 2021
|
English | 145.9 KB | ||
| 2021-05-19 21:18 |
Financial Results for the Three Months Ended March 31, 2021
|
English | 36.0 KB | ||
| 2021-05-19 21:10 |
Form 20-F/A Amendment No. 1 for the fiscal year ended December 31, 2020
|
English | 924.0 KB |
Automate Your Workflow. Get a real-time feed of all XTL Biopharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for XTL Biopharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for XTL Biopharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
